This analysis revealed significant changes in variables positively impacting CIS in patients achieving a response (decrease in CRP [p < 0.001], IL-6 [p < 0.001], and ferritin [p = 0.006]; increase in absolute lymphocyte count [p < 0.001]). The gene discussed is CRP; the disease is in situ carcinoma.